Weight Loss Injections Linked to Increased Risk of Nail Problems, Study Finds

A recent study suggests that individuals using weight loss injections may face an increased risk of nail-related problems, including fingernail detachment, which was found to be more than four times as common in users of these medications compared to non-users. The research, presented at the European Academy of Dermatology and Venereology Congress in Austria, also indicated that approximately 60 percent of patients on these drugs experience conditions such as loose nails and discoloration.

Experts hypothesize that medications like Ozempic, Wegovy, and Mounjaro, which are GLP-1 agonists, could trigger nutrient deficiencies. This may lead to a lack of keratin, a protein crucial for nail formation. The study compared 575 users of weight loss injections with 1,329 patients who had type 2 diabetes, obesity, or both, but had not taken the drugs. Among injection users, 66 percent reported at least one nail disorder, compared to 53 percent of the control group.

Nail discoloration was also significantly more prevalent in weight loss drug users, affecting 46 percent compared to 17 percent of others. Even when compared to individuals who lost weight through diet and exercise, jab users were still more likely to report nail problems. Researchers propose that the rapid weight loss induced by these drugs can stress the body, diverting nutrients and resources away from less essential functions like nail growth. Severe calorie restriction could also contribute to deficiencies in essential nutrients for nail health, such as iron, zinc, and biotin.

Beyond nail issues, the study also explored the impact of these injections on the scalp. Users of the jabs reported increased hair shedding, with about half experiencing this, compared to just over a third of non-users. Hair thinning affected over 40 percent of slimmers, and scalp redness was approximately three times more frequent in this group. These scalp symptoms often accompanied hair loss, suggesting a potential inflammatory component beyond the typical shedding seen after rapid weight loss. Doctors have noted that while these side effects are treatable with topical medications, they are often overlooked.

Dr. Charles Taïeb, the lead author, emphasized that the observed effects on skin, hair, and nails are not merely anecdotal. While hair thinning is a known common side effect listed for these drugs, official reports also highlight concerns. Data from the UK's Medicines and Healthcare products Regulatory Agency revealed hundreds of reports of hair loss linked to tirzepatide (the active ingredient in Mounjaro) since early 2025, with hundreds more associated with Wegovy and Ozempic. Previous analyses suggest this hair loss is a form of non-scarring alopecia, where hair follicles remain intact, potentially allowing for regrowth.